Jenkins’ Exit Interview: He’ll Miss Insider Status Upon FDA Departure

Once he retires from FDA next month, John Jenkins will have to consume FDA actions later than he has become accustomed to since becoming Office of New Drugs director, and he says he’ll miss being deluged with a variety of scientific and regulatory conundrums.

"I bounce every day from meeting to meeting to meeting; every one [has] interesting and complex scientific, regulatory and legal topics that you don’t have exposure to when you're not